Grifols (GRFS) Stock Forecast and Price Target (2026)

Sell-side coverage follows trading volume and banking relationships, so smaller companies, recent listings, and names outside the major indices often carry little or none. That is the situation with GRFS. It says nothing about the quality of the business, but it does mean there is no informed average to anchor to, and that any single target you find elsewhere is one analyst's model rather than a consensus.

As of October 16, 2026 the ADR trades near $7.72, about 10x trailing and 5x forward earnings and roughly 0.7x sales, a deeper discount to plasma peers like CSL than in mid-2026 after a weak second quarter. The low forward multiple rests on analysts expecting 2026 EPS growth of about 35% and 2027 growth of about 24%, while roughly EUR 9.4 billion of debt means much of the enterprise value still sits with lenders, which is why deleveraging remains the key equity lever. The two analysts in Yahoo's consensus rate the ADR a buy with a mean target near $10.86.

For the fiscal year ending Dec 2026, the 11 analysts publishing estimates on GRFS expect earnings of $1.16 per share (+35% on the year before) and revenue of 7.7 billion EUR (+2.1%).

Estimates are the most widely published forecast there is: many more analysts model a company's earnings than publish a price target on it. They are also revised constantly, and the direction of those revisions into a report is often more informative than the level. Grifols next reports on July 28, 2026, which is when these figures get tested against actual results.

Not a published one. Analyst price targets run to about twelve months, occasionally two years, and the firms covering GRFS do not put out a 2030 number. Anything presenting one is extrapolating a growth rate rather than reporting research, and a figure produced that way tells you about the assumption chosen, not about the company.

The furthest-out consensus that exists is for the fiscal year ending Dec 2027: analysts expect earnings of $1.44 per share, +24% on the fiscal year ending Dec 2026 estimate of $1.16. Beyond that, nobody publishes estimates, so any later number is an extrapolation.

On the figures we hold as of October 2026, GRFS trades at about 9.8 times trailing earnings and 5.3 times forward earnings. A forward multiple below the trailing one means the market expects earnings to grow, and the size of that gap is roughly how much growth is already in the price.

That is the more useful frame for a ten-year question. A share price is the market’s estimate of future cash flows discounted to today, so the multiple is already a statement about growth. The long-horizon question is whether Grifols can deliver what is priced in, and what would have to change for that to break. Both are answerable from the drivers and risks below. A number for 2030 is not.

In short: the drivers cited most often are Immunoglobulin demand and volume growth, Margin recovery from lower cost-per-liter, Deleveraging and debt refinancing. The risk cited most often against it is grifols carries a heavy debt load, with leverage still above 4x, so its equity value is sensitive to interest rates, refinancing terms, and any stumble in cash generation.

Both sides are worked through properly, with the high and low targets used as the bull and bear anchors, on the GRFS is it a buy page. This page deliberately stops at the numbers.